Navigation Links
Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntington's Disease Model
Date:9/16/2008

8 in the online version of the Proceedings of the National Academy of Sciences.

"The marked reduction in symptoms achieved in the Huntington's disease model without overt toxicity defines a second disease target for our HDAC inhibitor program," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "We plan to continue to evaluate the utility of our novel HDAC inhibitors as a potential treatment for both Friedreich's ataxia and Huntington's disease."

Huntington's disease is caused by a trinucleotide repeat expansion in the Huntington's disease gene (Htt) that results in production of a mutant misfolded protein that is unable to function correctly. Huntington's disease is characterized by dysregulation in the transcription of hundreds of genes in the brain, leading to Huntington's symptoms ranging from jerky and random movements to impaired thinking and perception. Huntington's disease is a familial disease, passed from parent to child through a mutation in the normal gene. Symptoms of Huntington's disease typically emerge between the ages of 30 and 50 and fall into three categories: motor, cognitive and psychiatric. Cognitive symptoms include slowed processing of information in the brain, resulting in communication and planning difficulties, while depression is the most common psychiatric symptom of Huntington's disease. Motor symptoms include lack of coordination, muscle spasms, and chorea. As the disease progresses, any function requiring muscle control is affected, leading to severe disability, incapacitation or loss of life due to complications 10 to 20 years after symptoms first appear. There are approximately 30,000 people in the United States with Huntington's disease and there is currently no safe and effective treatment for the disease.

Repligen licensed the exclusive rights to intellectual property covering HDAC inhibitors from The Scripps Research Institute in April 2007 following which Repligen estab
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar will ... and clinical safety assessment in biosimilars. , Regulatory frameworks ... biosimilar drug development, however the complex nature of biopharmaceuticals ... safety and efficacy extremely challenging. Based on the specific ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 DTS Language ... its Online Web Portal for Life Science organizations who need ... specify the subject matter of their documents in advance with ... help reduce time-to-delivery of translations, often a critical factor in ...
(Date:1/14/2014)... PA (PRWEB) January 14, 2014 Date: Friday, ... , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... national nonprofit organization solely dedicated to finding a cure for ... affected worldwide, will host its annual Crystal Ball on Friday, ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... widely used as a navigational tool in vehicles from ... vehicle on three axes to evaluate its exact position ... School of Physical Engineering is now scaling down this ... and more futuristic technologies. Working in collaboration with ...
... 5 Regenicin™, Inc. (OTC Bulletin Board: ... announced today that Mr. Christopher A. Hadsall, whose primary ... to join the company as Chief Operating Officer.  Mr. ... Regenicin™ and will be instrumental in working with various ...
... MiMedx Group, Inc. (OTC Bulletin Board: ... patent protected biomaterial-based products, announced today that its results ... be released before the opening of the market on ... live broadcast of its third quarter conference call on ...
Cached Biology Technology:A tracking device that fits on the head of a pin 2Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer 2Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer 3MiMedx Group, Inc. Announces Release Date For Third Quarter Results 2
(Date:4/23/2014)... of Toronto Scarborough research shows that male black widow ... a rare example of mate preference by male ... post-doc Emily MacLeod and Maydianne Andrade, a professor in ... field studies and the wild that males overwhelmingly chose ... male black widows can tell whether a potential mate ...
(Date:4/23/2014)... Putnam Valley, NY. (Apr. 23, 2014) People who ... little potential to restore neurological function. However, a study ... future issue of Cell Transplantation , but is ... at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1168Chen , has found that when one ... stem cells (PBSCs) injected directly into the brain and ...
(Date:4/23/2014)... boom has transformed the energy landscape in the ... cause conflict among the energy industry, residents and ... They add that degraded water quality is a ... feature article appears in the ACS journal ... Mauter and colleagues point out that a major ...
Breaking Biology News(10 mins):Picky male black widow spiders prefer well-fed virgins 2Autologous stem cell therapy improves motor function in chronic stroke victims 2How to avoid water wars between 'fracking' industry and residents 2
... scientist Dr. Gadi V.P. Reddy is concerned about ... health of island residents and ecosystems. He has ... use and has recently been awarded an $188,000 ... (USDA-NIFA) Pest Management Alternatives Program (PMAP). Dr. Monte ...
... PA, June 24, 2011 Adolescents who diet and ... behaviors and binge eating) carry these unhealthy practices into ... by University of Minnesota researchers and published in the ... American Dietetic Association . "The findings from the ...
... applications in reconstructive and cosmetic surgery and in the food ... prolines within the protein need to be hydroxylated. BioMed Central,s ... the first time the α1 chain of type 1 collagen ... hydroxylation to human collagen. Most collagen used is derived ...
Cached Biology News:UOG scientist wins USDA competitive funding 2Adolescents' dieting and disordered eating behaviors continue into young adulthood 2Adolescents' dieting and disordered eating behaviors continue into young adulthood 3